Phase II Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer

Diseases and Conditions Researched

Cancer

What is the purpose of this trial?

Primary Objective:
-To assess the incidence of grade 3 or higher drug related adverse event in the study population during the induction period of ipilimumab (Day 1 of treatment to Week 24).
Secondary Objective:
-To assess the best overall response rate (BORR) in the study population by mWHO, immune-related response criteria (irRC), and CA125 Rustin Criteria. [Rustin, GJ 1996; Gordon, JS 2003]


Participation Guidelines

Age: 18 Years and older
Gender: Female

Click here for detailed participation information for this trial.

Sponsor: Bristol-Myers Squibb Company
Dates:
Last Updated:
Study HIC#: 1207010549